CN106360666A - Astaxanthin-containing anti-oxidation nutritional health product - Google Patents
Astaxanthin-containing anti-oxidation nutritional health product Download PDFInfo
- Publication number
- CN106360666A CN106360666A CN201610703260.4A CN201610703260A CN106360666A CN 106360666 A CN106360666 A CN 106360666A CN 201610703260 A CN201610703260 A CN 201610703260A CN 106360666 A CN106360666 A CN 106360666A
- Authority
- CN
- China
- Prior art keywords
- astaxanthin
- group
- oxidation
- nutrient
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 title claims abstract description 40
- 235000013793 astaxanthin Nutrition 0.000 title claims abstract description 40
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 title claims abstract description 40
- 229940022405 astaxanthin Drugs 0.000 title claims abstract description 40
- 239000001168 astaxanthin Substances 0.000 title claims abstract description 40
- 230000003064 anti-oxidating effect Effects 0.000 title claims abstract description 21
- 230000036541 health Effects 0.000 title abstract description 9
- 235000016709 nutrition Nutrition 0.000 title abstract description 7
- 239000000284 extract Substances 0.000 claims abstract description 29
- 239000009636 Huang Qi Substances 0.000 claims abstract description 18
- 239000000843 powder Substances 0.000 claims abstract description 15
- 235000015097 nutrients Nutrition 0.000 claims description 28
- 230000032683 aging Effects 0.000 abstract description 6
- 230000036039 immunity Effects 0.000 abstract description 2
- 230000001934 delay Effects 0.000 abstract 1
- 230000003078 antioxidant effect Effects 0.000 description 23
- GZCGUPFRVQAUEE-KCDKBNATSA-N aldehydo-D-galactose Chemical compound OC[C@@H](O)[C@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-KCDKBNATSA-N 0.000 description 21
- 210000002966 serum Anatomy 0.000 description 18
- 241000699670 Mus sp. Species 0.000 description 17
- 150000003254 radicals Chemical class 0.000 description 14
- 238000002474 experimental method Methods 0.000 description 13
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- 239000007924 injection Substances 0.000 description 10
- 238000002347 injection Methods 0.000 description 10
- 230000003647 oxidation Effects 0.000 description 10
- 238000007254 oxidation reaction Methods 0.000 description 10
- 230000006378 damage Effects 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 239000000203 mixture Substances 0.000 description 8
- 230000036542 oxidative stress Effects 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 230000001629 suppression Effects 0.000 description 7
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 6
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 6
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 6
- -1 lipid peroxide Chemical class 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 239000001301 oxygen Substances 0.000 description 6
- 229910052760 oxygen Inorganic materials 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 102000004506 Blood Proteins Human genes 0.000 description 5
- 108010017384 Blood Proteins Proteins 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 239000003963 antioxidant agent Substances 0.000 description 5
- 235000006708 antioxidants Nutrition 0.000 description 5
- 235000003969 glutathione Nutrition 0.000 description 5
- 229960003180 glutathione Drugs 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 4
- 230000006315 carbonylation Effects 0.000 description 4
- 238000005810 carbonylation reaction Methods 0.000 description 4
- 235000021466 carotenoid Nutrition 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 230000004792 oxidative damage Effects 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 3
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000005013 brain tissue Anatomy 0.000 description 3
- 150000001747 carotenoids Chemical class 0.000 description 3
- 230000005779 cell damage Effects 0.000 description 3
- 208000037887 cell injury Diseases 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 108700026460 mouse core Proteins 0.000 description 3
- 230000001590 oxidative effect Effects 0.000 description 3
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 3
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000972773 Aulopiformes Species 0.000 description 2
- 241000238557 Decapoda Species 0.000 description 2
- 241000371997 Eriocheir sinensis Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 description 2
- 108010012715 Superoxide dismutase Proteins 0.000 description 2
- 108010093894 Xanthine oxidase Proteins 0.000 description 2
- 102100033220 Xanthine oxidase Human genes 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000003859 lipid peroxidation Effects 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 150000002978 peroxides Chemical class 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 239000002516 radical scavenger Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 235000019515 salmon Nutrition 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- HORQAOAYAYGIBM-UHFFFAOYSA-N 2,4-dinitrophenylhydrazine Chemical compound NNC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O HORQAOAYAYGIBM-UHFFFAOYSA-N 0.000 description 1
- LBEMXJWGHIEXRA-UHFFFAOYSA-N 2-[(2-carboxyphenyl)disulfanyl]benzoic acid Chemical compound OC(=O)C1=CC=CC=C1SSC1=CC=CC=C1C(O)=O LBEMXJWGHIEXRA-UHFFFAOYSA-N 0.000 description 1
- KIUMMUBSPKGMOY-UHFFFAOYSA-N 3,3'-Dithiobis(6-nitrobenzoic acid) Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(SSC=2C=C(C(=CC=2)[N+]([O-])=O)C(O)=O)=C1 KIUMMUBSPKGMOY-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 238000012271 agricultural production Methods 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003674 animal food additive Substances 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000007398 colorimetric assay Methods 0.000 description 1
- LBJNMUFDOHXDFG-UHFFFAOYSA-N copper;hydrate Chemical compound O.[Cu].[Cu] LBJNMUFDOHXDFG-UHFFFAOYSA-N 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003617 erythrocyte membrane Anatomy 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- 239000007952 growth promoter Substances 0.000 description 1
- 235000001497 healthy food Nutrition 0.000 description 1
- 125000001867 hydroperoxy group Chemical group [*]OO[H] 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000005065 mining Methods 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- JPXMTWWFLBLUCD-UHFFFAOYSA-N nitro blue tetrazolium(2+) Chemical compound COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC(=CC=2)[N+]([O-])=O)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=C([N+]([O-])=O)C=C1 JPXMTWWFLBLUCD-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 150000002926 oxygen Chemical class 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000009145 protein modification Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- MUUHXGOJWVMBDY-UHFFFAOYSA-L tetrazolium blue Chemical compound [Cl-].[Cl-].COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC=CC=2)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 MUUHXGOJWVMBDY-UHFFFAOYSA-L 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses an astaxanthin-containing anti-oxidation nutritional health product. The astaxanthin-containing anti-oxidation nutritional health product is produced from astaxanthin powder, Radix Astragali extract and Ligustri Lucidi Fructus extract according to a mass ratio of (1.5-2.5):(1-2):1. The Radix Astragali extract and the Ligustri Lucidi Fructus extract in the astaxanthin-containing anti-oxidation nutritional health product can substantially enhance the anti-oxidation ability of astaxanthin, and the obtained nutritional health product substantially improves the anti-oxidation ability of human bodies, improves the immunity of the human bodies, delays ageing and provides guaranteeing for the health of the human bodies.
Description
Technical field
The invention belongs to health product technology field is and in particular to a kind of antioxidation nutrient and healthcare products containing astaxanthin.
Background technology
Oxidation is the biggest threat of skin aging, diet is unhealthy, Exposure to Sunlight, pressure, environmental pollution etc. can allow skin from
Being spread unchecked by base, thus producing the oxidative phenomenas such as complexion dimness, hydropenia, being all that body produces oxidation " arch-criminal ".Normal
In the case of, the free radical in human body is among the dynamic equilibrium that constantly produces and remove.Free radical produces excessive or removes
Cross slow, it passes through to attack life macromolecule material and various cell, can cause body in molecular level, cellular level and organizer
The various damages of official's level, accelerate the senescence process of body and induce various diseases.Human body is being inevitably generated free radical
While, also naturally producing the antioxidant resisting free radical, to offset the oxidative attacks to human body cell for the free radical.
Research has shown that, the antioxidant system of human body be one can comparable with immune system, have improve and complicated function be
System, body antioxidative ability is stronger, and more healthy, life is also longer.The antioxidation of body, can keep the product of free radical
Raw with the balance eliminating, to prevention disease with anti-ageing wait for a long time significant.
Astaxanthin (astaxanthin), also known as " ASX ", is a kind of from shrimp Eriocheir sinensiss shell, Concha Ostreae, salmon and algae, funguses
The Red carotenoids of middle discovery.The same with most animals, the mankind can not synthesize carotenoidses material in vivo, also only
Can be taken in by food and obtain, such as aquatic products, such as just contain astaxanthin in shrimp, Eriocheir sinensiss and some cold water fishes, become people and mend
Fill the animality source of carotenoid.There are some researches show in recent years, natural astaxanthin has stronger antioxidant activity, has
Remove free radical, protection blood vessel, reduce cholesterol, skin protection, protection vision, protection nervous system, prevention senile dementia, alleviate and close
Many nutrition health-care functions such as section pain；Particularly natural astaxanthin has strong antioxidant activity, is referred to as " super
Vitamin e ", " super antioxidant ".A large amount of human trials of natural astaxanthin and animal experiment verified it be a kind of non-
The carotenoid of Chang Anquan.In Japan, natural astaxanthin also has been used for food and animal feed, U.S. fda, European Union, Canada
Food surveillance office also approved it as salmon class feed additive.Because it has multiple biological effects, in nutrition and medicine
In application there is vast potential for future development, particularly astaxanthin as the mankind high-class healthy food have boundless should
Use prospect.
Content of the invention
It is an object of the invention to provide a kind of battalion of the antioxidation containing astaxanthin that can improve human body oxidation resistance
Foster health product.
The purpose of the present invention is achieved by the following technical solution:
A kind of antioxidation nutrient and healthcare products containing astaxanthin, are to be extracted by astaxanthin powder, Radix Astragali extract and Fructus Ligustri Lucidi
Thing is obtained according to the mass ratio of 1.5-2.5:1-2:1.
Preferably, a kind of antioxidation nutrient and healthcare products containing astaxanthin, are by astaxanthin powder, Radix Astragali extract and Fructus Ligustri Lucidi
Seed extract is obtained according to the mass ratio of 2:1.5:1.
The preparation method of the described antioxidation nutrient and healthcare products containing astaxanthin is: by astaxanthin powder, Radix Astragali extract and
Fructus Ligustri Lucidi extract mix homogeneously, packs after sterilizing, you can the antioxidation nutrient and healthcare products containing astaxanthin.
Beneficial effects of the present invention: the present invention contains Radix Astragali extract and female in the antioxidation nutrient and healthcare products of astaxanthin
Loyal seed extract can significantly increase the oxidation resistance of astaxanthin, and gained nutrient and healthcare products are remarkably improved human body antioxidation energy
Power, improves body immunity, slow down aging simultaneously, is that health provides safeguard.
Brief description
The experimental result of the impact to Mouse Weight for the Fig. 1.
In figure: abscissa represents the time, vertical coordinate represents Mouse Weight change percentage ratio；Control is matched group, d-
Galactose is oxidativestress damage group, and 0.02mg/g is low dose group, and 0.15mg/g is middle dose group, and 0.6mg/g is high agent
Amount group, similarly hereinafter.
The experimental result that Fig. 2 affects on mice serum lipid oxidation products (mda).
In figure: abscissa represents packet, vertical coordinate represents mda concentration；* represent and there is significant difference, * * represents to be had
Pole significant difference, similarly hereinafter.
The experimental result that Fig. 3 affects on mice serum protein carbonylation content.
In figure: abscissa represents packet, vertical coordinate represents the concentration of protein carbonylation.
The experimental result to mice serum sod activity influence for the Fig. 4.
In figure: abscissa represents packet, vertical coordinate represents sod activity.
The experimental result that Fig. 5 affects on mice serum gsh content.
In figure: abscissa represents packet, vertical coordinate represents gsh content.
Specific embodiment
With reference to specific embodiment, the present invention is described further.
Raw material used by the present invention is market and buys gained.
Embodiment 1
A kind of antioxidation nutrient and healthcare products containing astaxanthin, are to be extracted by astaxanthin powder, Radix Astragali extract and Fructus Ligustri Lucidi
Thing is obtained according to the mass ratio of 1.5:2:1.
The preparation method of described antioxidative nutrient and healthcare products is: astaxanthin powder, Radix Astragali extract and Fructus Ligustri Lucidi are extracted
Thing mix homogeneously, packs after sterilizing, you can prepared antioxidative nutrient and healthcare products.
Embodiment 2
A kind of antioxidation nutrient and healthcare products containing astaxanthin, are to be extracted by astaxanthin powder, Radix Astragali extract and Fructus Ligustri Lucidi
Thing is obtained according to the mass ratio of 2:1.5:1.
The preparation method of described antioxidative nutrient and healthcare products is: astaxanthin powder, Radix Astragali extract and Fructus Ligustri Lucidi are extracted
Thing mix homogeneously, packs after sterilizing, you can prepared antioxidative nutrient and healthcare products.
Embodiment 3
A kind of antioxidation nutrient and healthcare products containing astaxanthin, are to be extracted by astaxanthin powder, Radix Astragali extract and Fructus Ligustri Lucidi
Thing is obtained according to the mass ratio of 2.5:1:1.
The preparation method of described antioxidative nutrient and healthcare products is: astaxanthin powder, Radix Astragali extract and Fructus Ligustri Lucidi are extracted
Thing mix homogeneously, packs after sterilizing, you can prepared antioxidative nutrient and healthcare products.
Impact to d- galactose model mice body weight
Choose female 10-12 monthly age balb/c mice.In addition to matched group, remaining animal 300mg/kg/dayd- gala
Sugared bw nape part subcutaneous injection or lumbar injection modeling, injection dosage 0.1ml/10g, once a day, and continuous modeling 6 weeks, take blood
Survey mda.Press blood mda experiment point matched group, oxidativestress damage group and (high, medium and low) 3 dosage groups, every group of each six realities
Test mice.The daily gavage antioxidative nutrient and healthcare products of every group of every mice: low dose group 0.02mg/g/day, middle dose group
0.15mg/g/day (5 times of human body recommended amounts), high dose group 0.6mg/g/day, are carried out continuously 30 days.In addition to matched group, its
Remaining experiment mice continues to inject d- galactose in medicine feed simultaneously, and experimental result is as shown in Figure 1.
As shown in Figure 1, d- galactose injection (oxidativestress damage group) causes the decline of Mouse Weight, and middle dose group can press down
Make the weight loss being caused by d- galactose.
Impact to serum lipids oxidation product (mda)
Detect Serum MDA md using tba method.Body passes through enzyme system and produces oxygen-derived free radicals, Hou Zheneng with non-enzyme system
Attack the polyunsaturated fatty acid (polyunsaturatedfattyacid, pufa) in biomembrane, cause lipid peroxy to be turned into
With, and therefore form lipid peroxide.As: aldehyde radical (malonaldehyde mda), ketone group, hydroxyl, carbonyl, hydroperoxy or interior peroxide
Base, and new oxygen-derived free radicals etc..Lipid peroxidation not only changes into activity chemistry agent active oxygen, i.e. non-free mafic
Lipidolysis product, and pass through chain type or chain type chain reaction, amplify active oxygen effect.Therefore, an initial work
Property oxygen can lead to the formation of a lot of lipidolysis products, and in these catabolites, some are harmless, and other then can cause carefully
Born of the same parents' metabolism and dysfunction, in addition dead.Oxygen-derived free radicals are not only through the peroxide of polyunsaturated fatty acid in biomembrane (pufa)
Change and cause cell injury, and cell injury can also be caused by the catabolite of lipid hydroperoxide.Thus the amount of test mda
The snperoxiaized degree of body inner lipid usually can be reflected, indirectly reflect the degree of cell injury.
The mensure of mda is usually cooperated with the mensure of serum endogenous superoxide dismutase (sod), sod vigor
The height indirect reaction ability of body scavenging activated oxygen, and the height indirect reaction of mda body cell is subject to free radical
The order of severity attacked, contributes to sending out of medical science, biology, pharmacology and industrial and agricultural production by the interpretation of result of sod and mda
Exhibition.Malonaldehyde (mda) in lipid peroxide catabolite can be condensed with thiobarbituricacidα-, forms red product, in 532nm
There is maximum absorption band at place, because substrate is thiobarbituricacidα- (thibabituricacidtba), so method claims tba method, packet and
Ibid, result is as shown in Figure 2 for experimental technique.
As shown in Figure 2, the injection (oxidativestress damage group) of d- galactose causes mice serum lipid oxidation products the third two
Aldehyde increases；The Serum MDA content that middle dose group suppression is caused by d- galactose increases, and has pole significant difference；Low
The Serum MDA content that dosage group suppression is caused by d- galactose increases, and has significant difference.
Impact to mice serum protein carbonyl group
Protein carbonylation is early sign during the oxidative modification of protein for the several amino acids, its content height
Show the size of protein oxidative damage degree, be to weigh one of important indicator of protein oxidative damage.
After protein occurs oxidative damage, it is red that its carbonylation product and 2,4 dinitrophenyl hydrazine (detection probe) react generation
Color 2,4- dinitrophenylhydrazone, produce characteristic absorption peak at 370nm.Ibid, result is as shown in Figure 3 for packet and experimental technique.
From the figure 3, it may be seen that the injection (oxidativestress damage group) of d- galactose causes mice serum content of protein carbonyl group to increase
High；High dose group can suppress the serum proteins carbonyl content being caused by d- galactose to increase, and has significant difference；Middle dosage
The serum proteins carbonyl content that group suppression is caused by d- galactose increases, and has pole significant difference；Low dose group suppression by
The serum proteins carbonyl content that d- galactose causes increases, and has pole significant difference.
Impact to serum endogenous antioxidant sod and gsh
Measure antioxidative nutrient and healthcare products to serum endogenous superoxide dismutase (sod) or reduced glutathion
(gsh) impact.
Sod is widely present in animal, plant, microorganism and cultured cells, and catalysis superoxide anion is disproportionated
Effect, generates h2o2And o2.Sod is not only superoxide anion scavenger enzyme, is also that hydrogen peroxide mainly generates enzyme, in biology
Play an important role in antioxidant system.The activity of sod detects according to nitroblue tetrazolium (nbt) method.First pass through xanthine and
Xanthine oxidase response system produces superoxide anion (o2-.), o2-.Reducible nitrogen blue tetrazolium generates blue first, Hou Zhe
There is absorption at 560nm；Sod can remove o2-., thus inhibiting the formation of first；Reactant liquor blueness is deeper, illustrates that sod activity heals
Low, on the contrary activity is higher, and result is as shown in Figure 4.
As shown in Figure 4, the injection (oxidativestress damage group) of d- galactose causes mice serum sod content to reduce；Middle dose
The mice serum sod content that the suppression of amount group is caused by d- galactose reduces, and has pole significant difference.
Reduced glutathion (gsh) is most important non-enzymatic polyphenoils in body, has removing free radical, solution
Malicious, the integrity promoting irony absorption and maintaining erythrocyte membrane, the biosynthesiss maintaining deoxyribonucleotide, cell normal
Multiple important physiological function such as growth promoter and cellular immunization.Glutathione is glutamic acid, glycine and cysteine composition
A kind of tripeptides, is the sulfhydryl compound of main nonprotein in tissue, and is two kinds of enzyme substrates of gsh-px and gsh-st,
Required for this two kinds of enzyme hydroperoxide decompositions, and can stably contain the enzyme of sulfydryl and prevent hemoglobin and other cofactors to be subject to
Oxidative damage.Gsh is a kind of low molecule scavenger, can remove h2o2、o2, looh, thus gsh amount number be weigh body resist
The key factor of oxidability size.Reduced glutathion (gsh) can react life with dithiobis benzoic acid potassium (dtnb)
Become a kind of yellow compound, colorimetric assay can be carried out under 405nm and measure reduced glutathion (gsh) content.Result such as Fig. 5
Shown.
As shown in Figure 5, the injection (oxidativestress damage group) of d- galactose causes mice serum gsh content to reduce；High agent
The serum gsh content that the suppression of amount group is caused by d- galactose reduces, and has significant difference；Middle dose group suppresses by d- galactose
The serum gsh content causing reduces, and has pole significant difference；The serum gsh that low dose group suppression is caused by d- galactose contains
Amount reduces, and has significant difference.
Oxidation resistance is tested
1. material: cleaning grade icr mouse inbred liness, male and female half and half, weight (19 ± 2) g, provided by Shanghai company.d-
Galactose is sigma Products；Sod, mda, gsh-px detection kit is purchased from Shanghai company.
2. packet and test method: 70 mices are randomly divided into 7 groups by body weight, respectively blank control group, old and feeble mould
Type group, experiment a group (the antioxidative nutrient and healthcare products of embodiment 1), test b group (the antioxidative nourishing healthy of embodiment 2
Product), experiment c group (the antioxidative nutrient and healthcare products of embodiment 3), matched group a, matched group b.In addition to blank control group, remaining
Each group daily give mouse peritoneal injection d- galactose 120mg/kg, continuous 8 weeks；Blank control group and aging model group are daily little
Mus intraperitoneal injection of saline.Meanwhile, experiment a group gives the antioxidative nutrient and healthcare products of mouse stomach embodiment 1 preparation daily
0.15mg/g；Experiment b group gives the antioxidative nutrient and healthcare products 0.15mg/g of mouse stomach embodiment 2 preparation daily；Experiment c group
Give the antioxidative nutrient and healthcare products 0.15mg/g of mouse stomach embodiment 3 preparation daily.Matched group a gives mouse stomach shrimp daily
Blue or green element powder 0.15mg/g, matched group b give the mixture 0.15mg/g of mouse stomach Radix Astragali extract and Fructus Ligustri Lucidi extract daily
(mass ratio of Radix Astragali extract and Fructus Ligustri Lucidi extract is 1.5:1).
3. setting room temperature is 20 DEG C about.Connect 8 weeks, after last dose, illustrate to measure the heart of mice by detection kit
Tissue homogenate sod vigor and mda content, gsh-px vigor in brain tissue homogenate.
4. result of the test: experimental data carries out variance analyses using statistics software.
4.1 aging model group mouse core tissue homogenate sod vigor, brain tissue homogenate's gsh-px vigor are less than blank control group
(p < 0.05), heart mda content dramatically increases (p < 0.05) compared with blank control group, and successful Application d- galactose lumbar injection is described
Method set up exhausted mining areas.
4.2 experiment a, b, c group mouse core tissue homogenate sod vigor, brain tissue homogenate's gsh-px vigor significantly improve (p <
0.05), heart mda content significantly reduces (p < 0.05).Matched group a, matched group b mouse core tissue homogenate sod vigor, cerebral tissue are even
Slurry gsh-px vigor improves (p < 0.1), and heart mda content reduces (p < 0.1).
With respect to matched group a, matched group b, it improves the work of body sod, gsh-px antioxidase to 4.3 experiment a, b, c groups
Range Du Genggao.
In this experiment, after the subacute aging mouse model set up by d- galactose injection (oxidativestress damage group),
After the nutrient and healthcare products of the present invention, improve the vigor of mice body sod, gsh-px antioxidase, thus promoting body
The elimination of interior free radical, mitigates lipid peroxidation and occurs, protect biomembrane, serves antioxidative effect, free radical simultaneously
Minimizing can also by the mechanism slow down aging of inhibited apoptosis, from experimental result 4.3 it can also be seen that present invention preparation anti-
The oxidation resistance of the nutrient and healthcare products of oxidation is better than astaxanthin powder and Radix Astragali extract and the female of single formula Isodose
The mixture of loyal seed extract, illustrates that astaxanthin powder and Radix Astragali extract and the mixture of Fructus Ligustri Lucidi extract combine through proportioning
Formula played the synergism of the two, there is the effect of more high-quality.
The above, the only present invention preferably specific embodiment, but protection scope of the present invention is not limited thereto,
Any those familiar with the art the invention discloses technical scope in, the change or replacement that can readily occur in,
All should be included within the scope of the present invention.Therefore, protection scope of the present invention should be with scope of the claims
It is defined.
Claims (2)
1. a kind of antioxidation nutrient and healthcare products containing astaxanthin are it is characterised in that be by astaxanthin powder, Radix Astragali extract and female
Loyal seed extract is obtained according to the mass ratio of 1.5-2.5:1-2:1.
2. antioxidation nutrient and healthcare products according to claim 1 are it is characterised in that be by astaxanthin powder, Radix Astragali extract
With Fructus Ligustri Lucidi extract according to 2:1.5:1 mass ratio be obtained.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610703260.4A CN106360666A (en) | 2016-08-22 | 2016-08-22 | Astaxanthin-containing anti-oxidation nutritional health product |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610703260.4A CN106360666A (en) | 2016-08-22 | 2016-08-22 | Astaxanthin-containing anti-oxidation nutritional health product |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106360666A true CN106360666A (en) | 2017-02-01 |
Family
ID=57878422
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610703260.4A Pending CN106360666A (en) | 2016-08-22 | 2016-08-22 | Astaxanthin-containing anti-oxidation nutritional health product |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106360666A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107927738A (en) * | 2017-12-13 | 2018-04-20 | 深圳地天国际生物工程科技有限公司 | A kind of Amti-sanility health-care food and its preparation process |
| CN108013439A (en) * | 2017-12-13 | 2018-05-11 | 深圳地天国际生物工程科技有限公司 | The cordyceps sinensis composition and its preparation process of a kind of anti-aging |
| CN108065353A (en) * | 2017-12-13 | 2018-05-25 | 深圳地天国际生物工程科技有限公司 | A kind of pre- anti-aging health food and its preparation process |
| CN108652002A (en) * | 2018-03-13 | 2018-10-16 | 云南爱尔康生物技术有限公司 | A kind of astaxanthin meal replacement powder and preparation method thereof |
| CN109247574A (en) * | 2018-11-26 | 2019-01-22 | 青岛浩然生物科技有限公司 | A kind of production method of natural astaxanthin and nostoc compound powder |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104491350A (en) * | 2014-12-27 | 2015-04-08 | 张标 | Health product capable of regulating health of heart and cerebral vessels and reducing risk of cardiovascular and cerebrovascular diseases |
| CN105394749A (en) * | 2015-10-23 | 2016-03-16 | 武汉龙族药号生物医药科技有限公司 | Formula, preparation method and application of astaxanthin-containing health food |
| CN105581332A (en) * | 2015-12-31 | 2016-05-18 | 石家庄中硕药业有限公司 | Composition with skin moisture improving and antioxidation functions and preparation method |
-
2016
- 2016-08-22 CN CN201610703260.4A patent/CN106360666A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104491350A (en) * | 2014-12-27 | 2015-04-08 | 张标 | Health product capable of regulating health of heart and cerebral vessels and reducing risk of cardiovascular and cerebrovascular diseases |
| CN105394749A (en) * | 2015-10-23 | 2016-03-16 | 武汉龙族药号生物医药科技有限公司 | Formula, preparation method and application of astaxanthin-containing health food |
| CN105581332A (en) * | 2015-12-31 | 2016-05-18 | 石家庄中硕药业有限公司 | Composition with skin moisture improving and antioxidation functions and preparation method |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107927738A (en) * | 2017-12-13 | 2018-04-20 | 深圳地天国际生物工程科技有限公司 | A kind of Amti-sanility health-care food and its preparation process |
| CN108013439A (en) * | 2017-12-13 | 2018-05-11 | 深圳地天国际生物工程科技有限公司 | The cordyceps sinensis composition and its preparation process of a kind of anti-aging |
| CN108065353A (en) * | 2017-12-13 | 2018-05-25 | 深圳地天国际生物工程科技有限公司 | A kind of pre- anti-aging health food and its preparation process |
| CN108652002A (en) * | 2018-03-13 | 2018-10-16 | 云南爱尔康生物技术有限公司 | A kind of astaxanthin meal replacement powder and preparation method thereof |
| CN109247574A (en) * | 2018-11-26 | 2019-01-22 | 青岛浩然生物科技有限公司 | A kind of production method of natural astaxanthin and nostoc compound powder |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106360666A (en) | Astaxanthin-containing anti-oxidation nutritional health product | |
| KR102239121B1 (en) | Sugar-free pineapple extract, method for producing the extract, and application of the extract | |
| JP4470212B2 (en) | Skin improver | |
| JP2021045127A (en) | Method for mass production of carotenoids | |
| JP2014019660A (en) | Active oxygen inhibitor | |
| JP2001200250A (en) | Antioxidant | |
| JP5226297B2 (en) | Method for producing at least one of 8-hydroxyliquiritigenin and 3'-hydroxyisoquiritigenin | |
| KR101320738B1 (en) | The method of extracting carotinoid pigments of micro algae and composition comprising the extracted fucoxanthin for preventing or treating obesity or diabetes | |
| Desai et al. | Spirulina: The wonder food of the 21st Century | |
| JP2011063563A (en) | Wrinkle-improving composition | |
| JP6005339B2 (en) | COMPOSITION HAVING ANTIOXIDANT ACTIVITY, AND FOOD AND BEVERAGE AND COSMETICS CONTAINING THE SAME | |
| JP2008110942A (en) | Antioxidant composition containing astaxanthin, zinc and selenium | |
| JP2009107965A (en) | Ceramide synthesis promoter, and external preparation for skin and food and drink | |
| CN106318748A (en) | Anti-oxidant wine | |
| JP5095893B2 (en) | Active oxygen scavenger | |
| CN101410371B (en) | Process for production of carotenoid | |
| JP2002235084A (en) | Antioxidant | |
| Mussagy et al. | Microbial astaxanthin: from bioprocessing to the market recognition | |
| JP2008208104A (en) | Antioxidant, and food and drink | |
| KR101672098B1 (en) | Composition for removing hangover comprising fermented rice rinse water | |
| JP2006070114A (en) | Method for preparing carotenoid-containing extract | |
| JP2012246244A (en) | Capillary regression inhibitor | |
| JP5422137B2 (en) | Whitening agent, tyrosinase activity inhibitor, melanin production inhibitor, and skin external preparation for whitening | |
| JP2010013416A (en) | Algae extract having hair-growing effect | |
| WO2023228994A1 (en) | Composition for enhancing sirt3 gene expression |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20170519 Address after: Qing Ping Road Qingpu District Xujing town Shanghai City Luzhou 201700 No. 2008 floor 10 room 1025 Applicant after: SHANGHAI NO-TOP BIOTECHNOLOGY CO., LTD. Address before: 200030 Shanghai city Xuhui District Yunjin Road No. 500 Green Exchange Center B building 17 floor Applicant before: Zhang Biao |
|
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20190116 Address after: Room 503, 5th floor, Daye Plaza, Jingheng, 2008, Shanghai Qingpu District, Shanghai Applicant after: Shanghai Yuanding Biotechnology Co., Ltd. Address before: Room 1025, 10th floor, 2008 Luqingping Road, Xujing Town, Qingpu District, Shanghai Applicant before: SHANGHAI NO-TOP BIOTECHNOLOGY CO., LTD. |
|
| TA01 | Transfer of patent application right | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170201 |
|
| RJ01 | Rejection of invention patent application after publication |